The company said the first quarter earnings amounted to $ 6.2 billion, equivalent to $ 2.32 per share, compared to $ 5.8 billion, equivalent to $ 2.17 per share from 2020.
"At the same time, the company's net profit after excluding private and non-recurrent items about $ 6.92 billion, equivalent to $ 2.59 per share, while analysts expect these profits to 2.34 Dollars per share.
The company's revenue, which produces an anti-Corona vaccine currently has been increased by 7.9% annually; To reach $ 22.32 billion in the first quarter of this year, compared with $ 20.69 billion for the same period in the previous year.
